CD47 is a cell surface glycoprotein that is expressed on normal human tissues and serves as a marker of self. Tumor cells have co-opted CD47 overexpression to evade immune surveillance, making blockade of CD47 an attractive strategy in oncology. However, clinical development of CD47-targeted agents has been complicated by its robust normal tissue expression. SGN-CD47M is a novel protease-activated anti-CD47 antibody that incorporates a functional IgG1 backbone whose binding and function is restricted to the tumor microenvironment. SGN-CD47M may have enhanced antitumor activity and improved tolerability relative to existing therapies that target CD47.

Pancreatic cancer is one of the most aggressive types of cancer with one of the lowest 5-year survival rates among all cancers. TROP2 is a promising therapeutic target in pancreatic cancer correlated with metastasis and poor prognosis. Here, Papacharisi and colleagues describe new TROP2 targeting ADCs containing the highly potent payload amanitin with a new mode of...

You do not currently have access to this content.